Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

The Exploratory Study of Patient-derived Organoids for the Prediction and Evaluation of Clinical Efficiency Effect of Colorectal Cancer Liver Metastasis

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

Inclusion Criteria:

• Histologically proven colorectal cancer with liver metastasis
• Aged between 18 and 70 years
• Written informed and signed consent
• Accessible to surgery sample of metastasis and primary tumor

Exclusion Criteria:

• Less than 18 years and older than 70 years
• Not able to give informed consent
• Not accessible to surgery sample